VANCOUVER, Feb. 20, 2015 /CNW/ - Aequus
Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to
announce that it has received a receipt (the "Receipt") for a final
prospectus filed with securities regulators in British Columbia, Alberta, Manitoba and Ontario (the "Jurisdictions") on February 19, 2015 (the "Prospectus"). The receipt
makes Aequus a reporting issuer in the Jurisdictions with all of
the reporting requirements associated with that status.
The Company has applied to list its common shares ("Common
Shares") on the TSX Venture Exchange ("TSX-V") and anticipates its
Common Shares will trade under the trading symbol "AQS". The
listing of the Common Shares is subject to the Company fulfilling
all of the listing requirements and the approval of the TSX-V. "To
begin trading on the TSX-V is a major milestone for Aequus, and
becoming a reporting issuer is a significant step toward achieving
that milestone," said Doug Janzen,
President and CEO of Aequus. "Once we are publicly traded, we will
be able to access larger pools of capital which will enable us to
aggressively grow our business."
Previously, on November 20, 2014,
the Company issued a total of 7,618,780 special warrants (the
"Special Warrants") and 425,521 agents' special warrants (the
"Agents' Special Warrants") of the Company. Pursuant to the terms
of the Special Warrants and Agents' Special Warrants, as a result
of the Company receiving the Receipt each Special Warrant and
Agents' Special Warrant will be deemed to be exercised for no
additional consideration. Each Special Warrant will be exercised
into one unit ("Unit") consisting of one Common Share and one-half
of one Common Share purchase warrant (each whole warrant, a
"Warrant"). Each Warrant will entitle the holder to acquire an
additional Common Share at a purchase price of C$0.75 during the period ending 24 months from
closing. Each Agents' Special Warrant will be exercised into one
agent warrant which will be exercisable to acquire one Unit at a
price of C$0.55 per agent warrant for
a period of 24 months from closing.
About Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc. is a Vancouver-based specialty pharmaceutical
company focused on enhancing delivery methods for approved drugs
and select consumer products that are limited by non-compliance,
high frequency dosing, first-pass metabolism side-effects, painful
injections, or where the therapeutic profile can be improved by
making a long-acting alternative available.
Forward-Looking Statement Disclaimer
This release contains forward-looking statements or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including,
without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward-looking
statements are necessarily based on estimates and assumptions made
by us in light of our experience and perception of historical
trends, current conditions and expected future developments, as
well as the factors we believe are appropriate. Forward-looking
statements in this release include but are not limited to
statements relating to: the intention to complete the
listing of the Common Shares on the TSX-V and all transactions,
listing requirements and approvals related thereto; the exercise of
the Special Warrants and Agents' Special Warrants; the
implementation of our business model and strategic plans; our
ability to access capital; and the Company's reporting
obligations.
Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by Aequus, are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance, or achievements
that may be expressed or implied by such forward-looking
statements. In making the forward looking statements included in
this release, the Company has made various material assumptions,
including, but not limited to general business and economic
conditions and the availability of financing on reasonable
terms.
In evaluating forward-looking statements, current and
prospective shareholders should specifically consider various
factors set out herein and under the heading "Risk Factors" in the
Prospectus, a copy of which is available on Aequus' profile on the
SEDAR website at www.sedar.com, and as otherwise disclosed from
time to time on Aequus' SEDAR profile. Should one or more of these
risks or uncertainties, or a risk that is not currently known to us
materialize, or should assumptions underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made
as of the date of this release and we do not intend, and do not
assume any obligation, to update these forward-looking statements,
except as required by applicable securities laws. Investors are
cautioned that forward-looking statements are not guarantees of
future performance and are inherently uncertain. Accordingly,
investors are cautioned not to put undue reliance on
forward-looking statements.
SOURCE Aequus Pharmaceuticals Inc.
